Defencath™ , an investigational drug product, is a novel, antimicrobial and antifungal solution being developed for the prevention of catheter-related bloodstream infections (“CRBSIs”) in patients with end-stage renal disease receiving hemodialysis through a central venous catheter.

Defencath™, an investigational drug product, was granted FDA Fast Track status and is designated as a Qualified Infectious Disease Product.